Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma |
| |
| Affiliation: | 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States;2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States;3. Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa, Japan;4. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, United States;5. Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, United States;6. Institute of Clinical Medicine; National Yang-Ming University, Taipei, Taiwan;1. Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA;2. Divsion of Hematology-Oncology, Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA 92307, USA;3. Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA;4. University Cancer and Blood Center, Athens, GA 30607, USA;5. Foundation Medicine Inc., Cambridge, MA 02141, USA;6. Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, USA;1. Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada;2. Division of Medical Oncology Department of Medicine, University of Ottawa and the Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada;3. NCIC Clinical Trials Group and Queen’s University, 10 Stuart Street, Kingston, Ontario K7L 3N6, Canada;4. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, and the University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada;1. Department of Pulmonary Diseases, VU University Medical Center, Boelelaan 1117, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands;2. Department of Pulmonary Diseases, GROW-School for Developmental Biology & Oncology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands;3. Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands;4. Department of Pulmonary Diseases, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands;5. Department of Pathology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands;6. Department of Pulmonary Diseases, Canisius Wilhelmina hospital, P.O. Box 9015, 6500 GS Nijmegen, The Netherlands;7. Department of Pathology, GROW-School for Developmental Biology & Oncology, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands;8. Department of Pulmonary Diseases, Spaarne Hospital, P.O. Box 770, 2130 AT Hoofddorp, The Netherlands;9. Department of Pulmonary Diseases, Rijnstate Hospital, P.O. Box 9555, 6800 TA Arnhem, The Netherlands;10. Department of Pulmonary Diseases, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE Amsterdam, The Netherlands;1. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan;2. Division of Respiratory Medicine, Chiba Cancer Center, Chiba, Japan;3. Division of Chemotherapy, Department of Internal Medicine, Japanese Red Cross Medical Center, Tokyo, Japan;4. Division of Pulmonary Medicine, Infection and Oncology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan;5. Thoracic Center, St. Luke''s International Hospital, Tokyo, Japan;1. University of Maryland Greenebaum Cancer Center, Baltimore, MD;2. Department of Medicine, University of Maryland School of Medicine, Baltimore, MD;3. Department of Pathology, University of Maryland School of Medicine, Baltimore, MD;4. Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD |
| |
| Abstract: | ObjectiveCD10 (neutral endopeptidase) is expressed in various normal and tumor cells, and its biological function can be controlled through enzymatic activity and signaling pathways. We investigated whether CD10 expression predicted disease recurrence and whether it correlated with histologic subtypes of stage I lung adenocarcinoma.Materials and methodsWe reviewed tumor slides of resected pathologic stage I lung adenocarcinomas (1995–2009). Tumors were classified according to the IASLC/ATS/ERS classification. CD10 immunohistochemistry was performed using tissue microarrays (n = 915). We combined the intensity (0–3) and distribution scores (0–2) for CD10 to create a total score (0–5). Risk of recurrence was estimated using competing risks methods.ResultsIn the training cohort (n = 313), risk of recurrence of patients with high tumoral CD10 (score > 1, n = 57) was significantly higher (5-year cumulative incidence of recurrence [CIR], 37%) than in those with low CD10 (score ≤ 1; n = 256; 5-year CIR, 16%; P < 0.001); this finding was confirmed in the validation cohort (n = 602, P = 0.036). High tumoral CD10 was associated with higher risk of recurrence in acinar (P = 0.007) and papillary predominant tumors (P = 0.022). High tumoral CD10 was most frequently identified in micropapillary predominant (41%) and solid predominant tumors (34%). On multivariate analysis of intermediate-grade tumors, high tumoral CD10 remained a significant independent risk factor of recurrence (hazard ratio, 1.88; P = 0.025).ConclusionIn stage I lung adenocarcinoma, tumoral CD10 correlated with high-grade histology and was an independent predictor of recurrence in intermediate-grade tumors. |
| |
| Keywords: | Adenocarcinoma Lung CD10 Histology Recurrence |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
